Sodium Oxodihydroacridinylacetate

Researchers Stop Vitiligo Progression. New hope for millions worldwide

Data released on May 24, 2013 from our preclinical study of a Pharmsyntez drug, sold under the trademark Neovir, has shown positive results in arresting vitiligo lesion progression in 73.3 percent of patients with an active form of vitiligo.


Dr. Igor Korobko, Chief Scientific Director of the non-profit Vitiligo Research Foundation, has reported a major breakthrough in vitiligo therapy development at the 10th EADV Spring Symposium in Krakow, Poland. Read more »»»


Research Study Abstract »»»


Download presentation from our website (pdf, 2.44 MB) or see it online via SlideShare (external link)



Dr. Igor Korobko, PhD, DSci, has presented the results of early clinical trials

Photo Copy

Product packaging (for illustration purposes only, see Disclaimer here below)

Neovir For Vitiligo Treatment 24 05 2013

Disclaimer of Endorsement and Liability

The Vitiligo Research Foundation (VRF) does not endorse or recommend any commercial products, processes, or services, including those mentioned here above.

It is not the intention of VRF to provide specific medical advice but rather to provide users with information to better understand their health and their diagnosed disorders. VRF urges you to consult with a qualified dermatologist for diagnosis and for answers to your personal questions.

image description

I support the petition to designate June 25 as Vitiligo World Day and save millions of people worldwide from social isolation and persecution.

To download this free file, please tell us a little bit about yourself.